Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus

PLoS Pathogens

Volumn 12, Issue 6, 2016, Pages

  Mukhopadhyay, Rupkatha ^a   Roy, Sujayita ^a   Venkatadri, Rajkumar ^a   Su, Yu Pin ^a   Ye, Wenjuan ^b   Barnaeva, Elena ^b   Mathews Griner, Lesley ^b   Southall, Noel ^b   Hu, Xin ^b   Wang, Amy Q ^b   Xu, Xin ^b   Dulcey, Andrés E ^b   Marugan, Juan J ^b   Ferrer, Marc ^b   Arav Boger, Ravit ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMETINE; GANCICLOVIR; PROTEIN TRANSLOCASE; ANTIVIRUS AGENT;

ANIMAL CELL; ARTICLE; CELL CYCLE REGULATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA REPLICATION; EC50; ENZYME INHIBITION ASSAY; IMMUNOPRECIPITATION; LOW DRUG DOSE; MOUSE; NONHUMAN; PLAQUE ASSAY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SELECTIVITY INDEX; SINGLE DRUG DOSE; TRANSIENT TRANSFECTION; VIROTHERAPY; VIRUS INHIBITION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL SURVIVAL; CYTOMEGALOVIRUS; DISEASE MODEL; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOBLOTTING; MALE; POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; EMETINE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 84978880831     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005717     Document Type: Article

References (65)

1. Griffiths PD, Clark DA, Emery VC, (2000) Betaherpesviruses in transplant recipients. J Antimicrob Chemother45Suppl T3: 29–34. 10855769
2. Kovacs A, Schluchter M, Easley K, Demmler G, Shearer W, et al. (1999) Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med341: 77–84. 10395631
3. Demmler GJ, (1991) Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis13: 315–329. 1645882
4. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK, (2013) The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev26: 86–102. 26/1/86 [pii];doi: 10.1128/CMR.00062-1223297260
5. Prichard MN, Kern ER, (2011) The search for new therapies for human cytomegalovirus infections. Virus Res157: 212–221. doi: 10.1016/j.virusres.2010.11.00421095209
6. Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, et al. (2009) Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother10: 191–209. doi: 10.1517/1465656080267813819236193
7. Steininger C, (2007) Novel therapies for cytomegalovirus disease. Recent Pat Antiinfect Drug Discov2: 53–72. 18221163
8. Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, et al. (2003) Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr143: 16–25. 12915819
9. Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, et al. (2015) Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med372: 933–943. doi: 10.1056/NEJMoa140459925738669
10. Jabs DA, Martin BK, Forman MS, (2010) Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS. Ophthalmology117: 128–132. doi: 10.1016/j.ophtha.2009.06.01619818505
11. Chou SW, (2001) Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis3Suppl 2: 20–24. 11926745
12. Krosky PM, Baek MC, Coen DM, (2003) The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol77: 905–914. 12502806
13. Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, et al. (2003) In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother47: 2186–2192. 12821466
14. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, et al. (2010) In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother54: 1290–1297. doi: 10.1128/AAC.01596-0920047911
15. Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, et al. (2011) First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant11: 1079–1084. doi: 10.1111/j.1600-6143.2011.03530.x21521474
16. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, et al. (2008) Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood111: 5403–5410. doi: 10.1182/blood-2007-11-12155818285548
17. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med14: 762–766. doi: 10.1038/nm177718552857
18. Thoene JG, Lemons R, Boskovich S, Borysko K, (1985) Inhibitors of protein synthesis also inhibit lysosomal proteolysis. Studies using cystinotic fibroblasts. J Clin Invest75: 370–376. 3973010
19. Entner N, Grollman AP, (1973) Inhibition of protein synthesis: a mechanism of amebicide action of emetine and other structurally related compounds. J Protozool20: 160–163. 4347870
20. Madjar JJ, Nielsen-Smith K, Frahm M, Roufa DJ, (1982) Emetine resistance in chinese hamster ovary cells is associated with an altered ribosomal protein S14 mRNA. Proc Natl Acad Sci U S A79: 1003–1007. 6122207
21. Zhou X, Hao Q, Liao J, Zhang Q, Lu H, (2013) Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene32: 388–396. doi: 10.1038/onc.2012.6322391559
22. Riley MF, Lozano G, (2012) The Many Faces of MDM2 Binding Partners. Genes Cancer3: 226–239. doi: 10.1177/194760191245532223150756
23. Kulikov R, Winter M, Blattner C, (2006) Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem281: 28575–28583. 16870621
24. Moll UM, Petrenko O, (2003) The MDM2-p53 interaction. Mol Cancer Res1: 1001–1008. 14707283
25. Worrall EG, Wawrzynow B, Worrall L, Walkinshaw M, Ball KL, et al. (2009) Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J Chem Biol2: 113–129. doi: 10.1007/s12154-009-0019-519568783
26. Zhang Z, Evers DL, McCarville JF, Dantonel JC, Huong SM, et al. (2006) Evidence that the human cytomegalovirus IE2-86 protein binds mdm2 and facilitates mdm2 degradation. J Virol80: 3833–3843. 80/8/3833 [pii];doi: 10.1128/JVI.80.8.3833-3843.200616571800
27. Lurain NS, Chou S, (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev23: 689–712. doi: 10.1128/CMR.00009-1020930070
28. Roy S, Arav-Boger R, (2014) New cell-signaling pathways for controlling cytomegalovirus replication. Am J Transplant14: 1249–1258. doi: 10.1111/ajt.1272524839861
29. Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY, et al. (2004) Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother48: 3516–3522. 15328119
30. Madjar JJ, Frahm M, McGill S, Roufa DJ, (1983) Ribosomal protein S14 is altered by two-step emetine resistance mutations in Chinese hamster cells. Mol Cell Biol3: 190–197. 6835209
31. Browne EP, Wing B, Coleman D, Shenk T, (2001) Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J Virol75: 12319–12330. 11711622
32. Hwang ES, Zhang Z, Cai H, Huang DY, Huong SM, et al. (2009) Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J Virol83: 12388–12398. JVI.00304-09 [pii];doi: 10.1128/JVI.00304-0919776115
33. Casavant NC, Luo MH, Rosenke K, Winegardner T, Zurawska A, et al. (2006) Potential role for p53 in the permissive life cycle of human cytomegalovirus. J Virol80: 8390–8401. 80/17/8390 [pii];doi: 10.1128/JVI.00505-0616912290
34. Fortunato EA, Spector DH, (1998) p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. J Virol72: 2033–2039. 9499057
35. Chen Z, Knutson E, Wang S, Martinez LA, Albrecht T, (2007) Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. J Biol Chem282: 29284–29295. M705349200 [pii];doi: 10.1074/jbc.M70534920017698841
36. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature387: 296–299. 9153395
37. Kubbutat MH, Jones SN, Vousden KH, (1997) Regulation of p53 stability by Mdm2. Nature387: 299–303. 9153396
38. Diaz JJ, Roufa DJ, (1992) Fine-structure map of the human ribosomal protein gene RPS14. Mol Cell Biol12: 1680–1686. 1549121
39. Boultwood J, (2011) The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome. Pediatr Rep3Suppl 2: e10. doi: 10.4081/pr.2011.s2.e10 pr.2011.s2.e10 [pii]. 22053272
40. Panettiere F, Coltman CA, Jr. (1971) Experience with emetine hydrochloride (NSC 33669) as an antitumor agent. Cancer27: 835–841. 4929936
41. Mastrangelo MJ, Grage TB, Bellet RE, Weiss AJ, (1973) A phase I study of emetine hydrochloride (NSC 33669) in solid tumors. Cancer31: 1170–1175. 4705155
42. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J22: 659–661. fj.07-9574LSF [pii];doi: 10.1096/fj.07-9574LSF17942826
43. Regenthal R, Krueger M, Koeppel C, Preiss R, (1999) Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput15: 529–544. 12578052
44. Knight R, (1980) The chemotherapy of amoebiasis. J Antimicrob Chemother6: 577–593. 6106010
45. Muhammad I, Dunbar DC, Khan SI, Tekwani BL, Bedir E, et al. (2003) Antiparasitic alkaloids from Psychotria klugii. J Nat Prod66: 962–967. 12880315
46. Carney RW, Wojtkunski J, Konopka EA, deStevens G, (1966) The chemical, spectral, and biological properties of monomethine cyanine dyes containing 1,3-benzoxazine and quinazoline nuclei. J Med Chem9: 758–762. 4381839
47. Rosenkranz V, Wink M, (2008) Alkaloids induce programmed cell death in bloodstream forms of trypanosomes (Trypanosoma b. brucei). Molecules13: 2462–2473. doi: 10.3390/molecules1310246218833031
48. Deng L, Dai P, Ciro A, Smee DF, Djaballah H, et al. (2007) Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol81: 13392–13402. 17928345
49. Chaves Valadao AL, Abreu CM, Dias JZ, Arantes P, Verli H, et al. (2015) Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity. Molecules20: 11474–11489. molecules200611474 [pii];doi: 10.3390/molecules20061147426111177
50. He R, Sandford G, Hayward GS, Burns WH, Posner GH, et al. (2011) Recombinant Luciferase-Expressing Human Cytomegalovirus (CMV) for evaluation of CMV inhibitors. Virol J8: 40. doi: 10.1186/1743-422X-8-4021269468
51. Lurain NS, Chou S, (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev23: 689–712. doi: 10.1128/CMR.00009-1020930070
52. Summers BC, Margolis TP, Leib DA, (2001) Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread. J Virol75: 5069–5075. 11333887
53. Fischer L, Laib SK, Jahn G, Hamprecht K, Gohring K, (2013) Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. Antiviral Res100: 575–577. S0166-3542(13)00286-6 [pii];doi: 10.1016/j.antiviral.2013.09.02624120366
54. Cai H, Kapoor A, He R, Venkatadri R, Forman M, et al. (2014) In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action. Antimicrob Agents Chemother58: 986–994. AAC.01972-13 [pii];doi: 10.1128/AAC.01972-1324277030
55. Bliss C.I, . (1939) The toxicity of poisons applied jointly. Ann Appl Biol26: 585–615.
56. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, et al. (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med18: 446–451. doi: 10.1038/nm.264922344296
57. Liu J, Xu Y, Stoleru D, Salic A, (2012) Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc Natl Acad Sci U S A109: 413–418. 1111561108 [pii];doi: 10.1073/pnas.111156110822160674
58. Iversen AC, Steinkjer B, Nilsen N, Bohnhorst J, Moen SH, et al. (2009) A proviral role for CpG in cytomegalovirus infection. J Immunol182: 5672–5681. doi: 10.4049/jimmunol.080126819380814
59. Vliegen I, Herngreen S, Grauls G, Bruggeman C, Stassen F, (2003) Improved detection and quantification of mouse cytomegalovirus by real-time PCR. Virus Res98: 17–25. 14609626
60. Lal A, Haynes SR, Gorospe M, (2005) Clean Western blot signals from immunoprecipitated samples. Mol Cell Probes19: 385–388. S0890-8508(05)00044-7 [pii];doi: 10.1016/j.mcp.2005.06.00716146684
61. Pizzorno MC, O'Hare P, Sha L, LaFemina RL, Hayward GS, (1988) trans-activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus. J Virol62: 1167–1179. 2831379
62. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, et al. (2008) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature451: 335–339. nature06494 [pii];doi: 10.1038/nature0649418202658
63. Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, et al. (2013) TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A110: 16127–16132. 1311055110 [pii];doi: 10.1073/pnas.131105511024043769
64. Tiscornia G, Singer O, Ikawa M, Verma IM, (2003) A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A100: 1844–1848. 12552109
65. Kapoor A, Forman M, Arav-Boger R, (2014) Activation of nucleotide oligomerization domain 2 (NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus replication. PLoS One9: e92704. doi: 10.1371/journal.pone.0092704 PONE-D-13-49464 [pii]. 24671169